Decision Analysis:安吉丽娜·朱莉正确?优化突变型BRCA携带者的癌症预防策略

2017-07-27 Beth 肿瘤资讯

自安吉丽娜·朱莉接受预防性的双乳房切除术后,引发一股BRCA1/2基因的检测高潮。事实上,在携带突变型BRCA1/2基因的女性中,很多会选择预防性手术来延长预期寿命,但这会影响后期的生育能力和生活质量。那么,这些女性在考虑生育计划时,应该做出怎样的决定?在考虑进行预防性手术时,应该在什么年龄进行?又应该以怎样的顺序选择手术才能使手术产生最大积极的影响?

自安吉丽娜·朱莉接受预防性的双乳房切除术后,引发一股BRCA1/2基因的检测高潮。事实上,在携带突变型BRCA1/2基因的女性中,很多会选择预防性手术来延长预期寿命,但这会影响后期的生育能力和生活质量。那么,这些女性在考虑生育计划时,应该做出怎样的决定?在考虑进行预防性手术时,应该在什么年龄进行?又应该以怎样的顺序选择手术才能使手术产生最大积极的影响?


携带突变型BRCA1/2基因的女性在其一生中,有45-65%会发生乳腺癌,15-39%会发生卵巢癌。在这些女性中,很多会选择预防性手术来延长预期寿命,包括双侧乳房切除术(BM),可使乳腺癌终生风险下降95%;双侧输卵管卵巢切除术(BOS),可使卵巢癌风险减少80%且进一步使乳腺癌风险减少60%。

虽然这些侵入性治疗可显着影响预期寿命,但同时也会引起相关并发症,包括激素副作用和对生育能力的影响,对生活质量也会造成影响。然而当病人考虑是否需要进行预防性手术时,并没有工具可以帮助患者做出艰难的决定,也没有指南阐明进行手术的最佳年龄以及最佳手术顺序。

针对这一问题, 一项发表在信息决策分析杂志,由奥托贝森管理研究院的Eike Nohdurft、Stefan Spinler及加州大学洛杉矶分校安德森管理学院的Elisa Long进行的新研究为医生和病人做出更明智的选择提供了见解。

这些研究者开发了一个决策分析模型,为那些携带BRCA突变基因的女性考虑进行何种预防性手术,应以怎样的顺序进行及在什么年龄手术产生最积极的影响提供了一个时间表。

根据研究结果,携带BRCA1突变基因的女性,推荐在30~60岁时首先进行BM治疗,在40岁之后再给予BOS治疗;而对于BRCA2基因突变人群,推荐首先进行BM治疗,理想年龄是40至46岁,在49岁之后再给予BOS治疗。

Nohdurft认为 “这项新见解可以允许女性综合考虑长期预防癌症的方法和其他因素,如生育计划,从而做出更明智的决策。”

点评

这项研究中构建的决策分析模型,可以帮助携带BRCA突变基因的女性在综合考虑癌症的长期预防,以及生育计划时做出更加明智的决定。而该模型是否能够真正有效的帮助病人,则需要进一步的验证。

原始出处:Eike Nohdurft, Elisa Long, Stefan Spinler. Was Angelina Jolie Right? Optimizing Cancer Prevention Strategies Among BRCA Mutation Carriers.Decision Analysis. July 12, 2017

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2017-12-24 sjq034
  2. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2017-10-24 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2018-06-16 经常头晕
  4. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2017-10-01 AspirantSuo
  6. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2018-07-11 qblt
  8. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2017-07-29 智智灵药
  10. [GetPortalCommentsPageByObjectIdResponse(id=1632466, encodeId=9ec5163246630, content=<a href='/topic/show?id=c74661143f0' target=_blank style='color:#2F92EE;'>#朱莉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61143, encryptionId=c74661143f0, topicName=朱莉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa6b21907690, createdName=sjq034, createdTime=Sun Dec 24 14:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949132, encodeId=7697194913298, content=<a href='/topic/show?id=3ccf1003558f' target=_blank style='color:#2F92EE;'>#预防策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100355, encryptionId=3ccf1003558f, topicName=预防策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 24 16:45:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700028, encodeId=56491e00028ef, content=<a href='/topic/show?id=295524e541' target=_blank style='color:#2F92EE;'>#Anal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2475, encryptionId=295524e541, topicName=Anal)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de3a29999500, createdName=经常头晕, createdTime=Sat Jun 16 05:45:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041365, encodeId=679f2041365c2, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 28 02:45:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633380, encodeId=afb016333803a, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Oct 01 22:45:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956532, encodeId=f99e195653284, content=<a href='/topic/show?id=ff385804c0' target=_blank style='color:#2F92EE;'>#DECISION#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5804, encryptionId=ff385804c0, topicName=DECISION)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1d2500084, createdName=1249884fm87暂无昵称, createdTime=Thu Oct 05 05:45:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004910, encodeId=a06e2004910c4, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Wed Jul 11 03:45:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993599, encodeId=57a419935997e, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 01 08:45:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594015, encodeId=c13c15940153c, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583933, encodeId=67e21583933cd, content=<a href='/topic/show?id=fe50e1502d9' target=_blank style='color:#2F92EE;'>#癌症预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71502, encryptionId=fe50e1502d9, topicName=癌症预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff416990595, createdName=12498e67m33暂无昵称, createdTime=Sat Jul 29 14:45:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]

相关资讯

广州多家三甲医院开遗传门诊 个人基因检测逐渐兴起

一滴血测肿瘤、3.5万元基因检测告诉你68种疾病风险和274种用药指导、20万元全基因检测告诉你健康风险……个人基因检测正成为“唐僧肉”。想要知晓自身甚至后代患病风险的人在考虑,测还是不测?怎么判断什么是靠谱的基因检测?

法制日报:防止基因检测成为迷信道具

通过基因技术能否检测出孩子有什么天赋?对此,世界卫生组织专门负责“儿童和青少年健康”方面的新闻官员曾公开表示,到目前为止,她还没有听说过检测基因可以预知一个孩子是否有音乐、绘画等天赋。可以说,基因和天赋的关系,目前科学上无任何定论,也不存在所谓的天赋基因。

Nat Genet:睾丸癌的基因检测指日可待!

使接受基因检测的健康男性能够知道他们是否是睾丸癌高危人群,这样一项最新研究离我们越来越近了。

卵巢癌日|七成患者发现已属晚期,哪些人群可做基因检测

5月8日是世界卵巢癌日,卵巢癌具有高死亡率、高复发率的特点,是严重威胁妇女健康的恶性肿瘤。亚洲卵巢癌发病率为6.1/10万,上海卵巢癌发病率为7.1/10万。目前在我国,卵巢癌死亡率居妇科恶性肿瘤之首。“卵巢很小,正常时位于盆腔内。由于盆腔大卵巢小,卵巢周围的空间相对较大,所以卵巢患恶性肿瘤时,七成不容易被发现,七成发现时已是晚期,七成发现后存活不过五年。”上海复旦大学附属肿瘤医院妇瘤科主任吴小华

BRCA数据解读中国专家共识

中华医学会病理学分会特组织分子病理学领域的相关专家进行了充分讨论,并形成共识发布,以指导与规范我国BRCA基因检测数据的解读,推动BRCA检测在我国的临床应用。

CCLM:基于三个不同HCV基因组区域的实时PCR对新cobas®HCV基因分型测试进行评估

丙型肝炎病毒(HCV)基因型的确定和丙型肝炎病毒亚型1a和1b的鉴定在抗HCV治疗开始前是强制性要求的。本研究的目的是评估最近推出的cobas®HCV GT测定(Roche)的性能,并将其与两种对照试验进行比较。